Biologics
The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and ...
March 18, 2026 | News
Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support&nb...
March 19, 2026 | News
-Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammat...
March 18, 2026 | News
Clinical Trial Approval (CTA) granted by Australia’s Therapeutic Goods Administration (TGA) for KMCAR™ T-cell, a first-in-human CAR-T cell th...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry,...
March 18, 2026 | News
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease...
March 18, 2026 | News
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has rec...
March 17, 2026 | News
Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special...
March 16, 2026 | News
PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. announced that they have entered into a drug discovery collaboration agreement (the "Collaborat...
March 16, 2026 | News
Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative du...
March 16, 2026 | News
Strategic investment reinforces Europe as a core pillar of GenScript's global R&D and production network, following recent U.S. facility...
March 13, 2026 | News
Most Read
Bio Jobs
News